Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture
December 22 2021 - 4:05PM
Business Wire
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology
company with a mission to discover, develop and deliver curative
therapies that address the underlying causes of heart disease,
today announced the appointments of Karah Parschauer, J.D., to its
Board of Directors and of Joanna Auch as Senior Vice President of
People and Culture.
“Tenaya is at an important inflection point in our growth and
maturity. We are now a public company with more than 100 employees
who represent our commitment to internalize critical capabilities,
including cGMP manufacturing and clinical development,” said Faraz
Ali, CEO of Tenaya. “Both Karah and Joanna are strong leaders who
bring highly relevant strategic and operational experiences to
Tenaya, and who also add to the diversity of our Board and our
leadership team. We welcome their contributions as Tenaya advances
TN-201 and TYA-11631 towards INDs in 2022.”
“I am delighted to join Tenaya’s Board of Directors at this
important moment in the company’s history,” said Ms. Parschauer.
“Tenaya is very well-positioned to take what the industry has
learned from drug development efforts for rare diseases and gene
therapies and to now apply that knowledge to advance potentially
disease-modifying therapies for patients and families fighting
severe genetic cardiomyopathies.”
Ms. Parschauer has nearly 20 years of relevant experience,
including with biopharmaceutical companies, with proven success in
corporate governance, mergers and acquisitions, and leading
organizations through growth and transformation. She currently
serves as Chief Legal Officer and Executive Vice President at
Ultragenyx Pharmaceutical Inc., a global biopharmaceutical company
advancing a diverse portfolio of approved therapies and product
candidates – including gene therapies – for ultra-rare genetic
diseases. Her previous experience includes over a decade in roles
of increasing responsibility at Allergan plc. Ms. Parschauer began
her legal career at Latham & Watkins LLP. She is currently a
member of the Board of Directors for Evolus, Inc. (NASDAQ: EOLS)
and Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB). Ms. Parschauer
earned her B.A. from Miami University and J.D. from Harvard Law
School.
Ms. Auch brings over 15 years of human resources experience
across various industries, including pharmaceutical, healthcare and
technology. She most recently served as Head of Human Resources for
North America at Santen, Inc., a global pharmaceutical company
focused on ophthalmology, where among other responsibilities she
led the human resources integration for two acquisitions. Ms. Auch
earned her B.A. from San Jose State University and is a member of
CSHRP, Community for Strategic HR Partnerships. She will report to
Tenaya’s CEO in a newly created role leading all aspects of human
resources including talent acquisition and management, culture and
values, compensation and benefits and organizational
effectiveness.
About Tenaya Therapeutics
Tenaya Therapeutics is a biotechnology company committed to a
bold mission: to discover, develop and deliver curative therapies
that address the underlying drivers of heart disease. Founded by
leading cardiovascular scientists from Gladstone Institutes and the
University of Texas Southwestern Medical Center, Tenaya is
developing therapies for rare genetic disorders as well as for more
prevalent heart conditions through three distinct but interrelated
product platforms: Gene Therapy, Cellular Regeneration and
Precision Medicine. For more information, visit
www.tenayatherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements as that
term is defined in Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Statements in
this press release that are not purely historical are
forward-looking statements. Words such as “expects” and “will,” and
similar expressions are intended to identify forward-looking
statements. Such forward-looking statements include, among other
things, statements by Tenaya’s chief executive officer and its
board members. The forward-looking statements contained herein are
based upon Tenaya’s current expectations and involve assumptions
that may never materialize or may prove to be incorrect. These
forward-looking statements are neither promises nor guarantees and
are subject to a variety of risks and uncertainties, including but
not limited to: risks associated with the process of discovering,
developing and commercializing drugs that are safe and effective
for use as human therapeutics and operating as an early stage
company; Tenaya’s ability to develop, initiate or complete
preclinical studies and clinical trials, and obtain approvals, for
any of its product candidates; the timing, progress and results of
preclinical studies for TN-201, TYA-11631 and Tenaya’s other
programs; Tenaya’s ability to raise any additional funding it will
need to continue to pursue its business and product development
plans; negative impacts of the COVID-19 pandemic on Tenaya’s
manufacturing and operations, including preclinical studies and
planned clinical trials; the timing, scope and likelihood of
regulatory filings and approvals; the potential for any clinical
trial results to differ from preclinical, interim, preliminary,
topline or expected results; Tenaya’s manufacturing,
commercialization and marketing capabilities and strategy; the loss
of key scientific or management personnel; competition in the
industry in which Tenaya operates; Tenaya’s reliance on third
parties; Tenaya’s ability to obtain and maintain intellectual
property protection for its product candidates; general economic
and market conditions; and other risks. Information regarding the
foregoing and additional risks may be found in the section entitled
“Risk Factors” in documents that Tenaya files from time to time
with the Securities and Exchange Commission. These forward-looking
statements are made as of the date of this press release, and
Tenaya assumes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211222005536/en/
Investors Leone Patterson Tenaya Therapeutics
IR@tenayathera.com Media Wendy Ryan Ten Bridge
Communications wendy@tenbridgecommunications.com
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Apr 2023 to Apr 2024